Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.85 |
| ▸ | STK25 | O00506 | 1/20 | 0.85 |
| ▸ | CIT | O14578 | 1/20 | 0.85 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.85 |
| ▸ | GAK | O14976 | 1/20 | 0.85 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.85 |
| ▸ | STK17B | O94768 | 1/20 | 0.85 |
| ▸ | STK10 | O94804 | 1/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | FES | P07332 | 1/20 | 0.85 |
| ▸ | CSF1R | P07333 | 1/20 | 0.85 |
| ▸ | YES1 | P07947 | 1/20 | 0.85 |
| ▸ | LYN | P07948 | 1/20 | 0.85 |
| ▸ | MET | P08581 | 1/20 | 0.85 |
| ▸ | HCK | P08631 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944414 | 0.93 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29349785 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93757 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93756 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29352012 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29385637 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29623744 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL20251032 | 0.90 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL12641774 | 0.89 | EGFR (0.72) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL22431978 | 0.88 | EGFR (0.80) | EGFRERBB2STK25CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110130706-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | EGFR 104/4885ERBB2 173/4885STK25 2238/4885 |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885STK25 124/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | EGFR 1834/4885ERBB2 734/4885STK25 289/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | EGFR 8/4885ERBB2 34/4885STK25 1106/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | EGFR 4244/4885ERBB2 3959/4885STK25 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.